Evidence map›Paper›PMID 34540003›Full record

ArticleAmerican journal of translational research2021

lncRNA PART1 mitigates MPP

Yue'e Shen, Xintao Cui, Nan Xu, Yuhang Hu, Zhenyu Zhang

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yue'e ShenDepartment of Neurology, The First Affiliated Hospital, Harbin Medical University Harbin, Heilongjiang Province, China.
Xintao CuiDepartment of Orthopedics, The First Affiliated Hospital, Harbin Medical University Harbin, Heilongjiang Province, China.
Nan XuDepartment of Anesthesiology, The Fourth Affiliated Hospital, Harbin Medical University Harbin, Heilongjiang Province, China.
Yuhang HuDepartment of Orthopedics, The First Affiliated Hospital, Harbin Medical University Harbin, Heilongjiang Province, China.
Zhenyu ZhangDepartment of Orthopedics, The First Affiliated Hospital, Harbin Medical University Harbin, Heilongjiang Province, China.
Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveParkinson's disease (PD) is a neurodegenerative disease caused by the loss of dopaminergic neurons. Here, we aimed to explore the function of LncRNA PART1 in PD and its underlying mechanisms.

methodsAn

resultsThe expression of LncRNA PART1 was decreased in PD model

conclusionLncRNA PART1 could alleviate the damage effects of MPP

Indexed as

LncRNA PART1microRNA-106b-5pMPP+Parkinson’s diseaseSH-SY5Y

Identifiers

PMID34540003
PMCPMC8430160
OpenAlexW3201072515

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.